Tarsus Pharmaceuticals

TARS

Market cap $3.08B

Tarsus Pharmaceuticals (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

TARS has passed the milestone of $100M in sales per quarter with Xdemvy. TARS guides for softer Q3'25 growth due to seasonality, but expects direct-to-consumer campaigns and reimbursement to drive stronger growth in Q4'25 and beyond. TARS pipeline includes international Xdemvy launches and a new ocular rosacea trial, offering significant future revenue potential beyond current indications.

IRVINE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:

For biotech firms, a bit of positive news—a key result from clinical trials or new drug discovery, say—can be the difference between a major rally based on a path toward sustained profitability and a slump that can lead to the firm's eventual demise.

As of Aug. 20, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

This biotech is nearing a buy point of a cup base. The company has a treatment for Lyme disease in its pipeline.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Aziz Mottiwala - Chief Commercial Officer Bobak R. Azamian - Co-Founder, President, CEO & Chairman David Nakasone - Head of Investor Relations Jeffrey S.

Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.88 per share a year ago.

Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY ® launch, an increase of 152% year over year

IRVINE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, August 6, 2025, to report its second quarter 2025 financial results and provide a corporate update.